MD, Medical School, Lady Hardinge Medical College, New Delhi, India
Internal Medicine Residency, University of Connecticut, Farmington, CT
Hematology Oncology Fellowship, Thomas Jefferson University, Philadelphia, PA
Dr. Shilpa Gupta is an Assistant Professor in the Hematology Oncology and Transplantation Division at the University of Minnesota. Dr. Gupta is a genitourinary oncologist and the Lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center.
Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India, after which she did a Fellowship in Emergency Medicine through the Royal College of General Practitioners, UK. She pursued a Master's in Health Informatics at the University of Minnesota and went on to do residency in Internal Medicine at the University of Connecticut Health Center where she consistently received awards for excellence in patient care. She completed her Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University and to pursue her strong interest in genitourinary cancers, she further did a genito-urinary translational research fellowship in Dr. Marja Nevalainen's laboratory at Thomas Jefferson University focusing on Jak2/Stat5 in prostate cancer and ex vivo prostate cancer models.
After completion of her fellowship in 2011, Dr. Gupta joined the H. Lee Moffitt Cancer Center and Research Institute/University of South Florida in Tampa, Florida as an Assistant Professor in the Departments of Genitourinary Oncology and Experimental Therapeutics where she had clinical, teaching and research responsibilities and stayed on staff until 2015.
She served as a panel member on the National Comprehensive Cancer Network (NCCN) committees for kidney and testicular cancers, and was a member of the NCCN subcommittee on testicular cancer to review the evidence and guidelines on follow-up of testicular cancer. Dr. Gupta is the Principal Investigator for several high-impact early phase clinical trials with novel targeted agents and immunotherapy agents, including the checkpoint inhibitors in genitourinary cancers; she has also been the Principal Investigator of translational research projects and projects involving computational modeling. She has presented her work at several national and international forums, including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Men’s Health World Congress, and the European society of Medical Oncology (ESMO) meetings. She has also been an invited speaker at several forums, including the Annual World Cancer Congress in Beijing where she discussed the role of novel therapeutics and preclinical models for personalized medicine in prostate cancer. Dr. Gupta has developed several clinical trials exploring targeted therapies and immunotherapies in genitourinary cancers, with a focus on bladder, kidney and prostate cancer.
- Bladder Cancer
- Prostate Cancer
- Kidney Cancer
- Penile Cancer
- Testicular Cancer
- Phase 1 trials solid tumors
- Phase 2, Phase 3 trials
- Targeted Therapy
Awards & Recognition
- Winner of Integrated Mathematical Oncology Team Prostate Award, Moffitt Cancer Center (2012)
- AACR/ASCO workshop on methods in clinical research, Vail, CO (2010)
- Award for excellence in patient care (2004, 2005, 2006)
- Fellow, Royal College of General Practitioners, U.K. (RCGP) (2001 - Present)
- American Urologic Association (AUA) (2015 - Present)
- Society of Immunotherapy of Cancer (SITC) (2014 - Present)
- Southwestern Oncology Group (SWOG) Genitourinary Committee (2012 - Present)
- Society of Urologic Oncology (SUO) (2012 - Present)
- European Society for Medical Oncology (ESMO) (2012 - Present)
- American Society of Clinical Oncology (ASCO) (2008 - Present)
- American Association for Cancer Research (AACR) (2009 - Present)